Prof. Dr. Steven Sutton | Microbiome Dysbiosis | Best Researcher Award
Professor at University of New England | United States
Prof. Dr. Steven Sutton, B.S.Pharm., Ph.D., FAAPS, FAAVPT, is a distinguished pharmaceutical scientist whose academic, industrial, and professional trajectory spans leadership in pharmaceutics education, biopharmaceutics innovation, regulatory influence, and multidisciplinary collaboration, beginning with foundational training in pharmacy and advanced doctoral specialization in pharmaceutics, followed by continuous contributions as Professor and former Chair in the Department of Pharmaceutical Sciences at the University of New England’s School of Pharmacy, where he has served in progressively senior academic roles while shaping curricular development, mentoring faculty and students, and advancing research in oral absorption, ADME prediction, dissolution, and drug development sciences; his earlier career includes significant industrial research leadership as Head of the Biopharmaceutics Group in Pharmaceutical Research and Development at Groton, scientific roles at Ciba-Geigy and INTERx/Merck Research Laboratories, and long-term Visiting Scientist appointments at major schools of pharmacy, complemented by advisory and adjunct professorial roles at the University of Connecticut, Kansas University, and the University of Missouri; he is honored as a Fellow of the American Association of Pharmaceutical Scientists and the American Academy of Veterinary Pharmacology and Therapeutics, recognized for substantial contributions to pharmaceutical sciences, modeling and simulation, regulatory science, and biopharmaceutics classification–based approaches; he has served on influential FDA expert panels, contributed to landmark white papers and scientific workshops, and provided long-standing editorial service to The AAPS Journal; his professional memberships span AAPS, AAVPT, Society of Toxicology, Controlled Release Society, and multiple discussion groups he helped found; his service includes extensive manuscript reviewing, mentoring initiatives, scientific workshop leadership, and consultancies for major pharmaceutical and biotechnology organizations; collectively, his career reflects sustained excellence, broad impact across academia, industry, and regulatory science, and a legacy of advancing pharmaceutics, biopharmaceutics, drug delivery, and therapeutic innovation.
Featured Publications:
AuthorLastName, A. A., AuthorLastName, B. B., AuthorLastName, C. C., & AuthorLastName, D. D. (2025). Plastic nanoparticle toxicity is accentuated in the immune-competent inflamed intestinal tri-culture cell model.
Digestion, media & mucous effects on nanoparticles (2023) AuthorLastName, A. A., & AuthorLastName, B. B. (2023). Effects of digestion, cell culture media, and mucous on the physical properties, cellular effects, and translocation of polystyrene and polymethacrylate nanoparticles.
Gut microbiome review (2019) AuthorLastName, A. A., AuthorLastName, B. B., AuthorLastName, C. C., AuthorLastName, D. D., … AuthorLastName, Z. Z. (2019). Gut microbiome: Profound implications for diet and disease.